PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure - BTG plc (LSE: BGC), has acquired US commercial rights to Wellstat Therapeutics Corporation’s product candidate uridine triacetate for use as a treatment for accidental overexposure to the chemotherapeutic 5-fluorouracil (5-FU)
BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/07/06 - BTG plc (LSE: BGC), has acquired US commercial rights to Wellstat Therapeutics Corporation’s product candidate uridine triacetate for use as a treatment for accidental overexposure to the chemotherapeutic 5-fluorouracil (5-FU). LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc (LSE: BGC), the specialist healthcare company, today announces that it has acquired US commercial rights to Wellstat Therapeutics Corporation’s product candidate uridine triacetate for use as a treatment for accidental overexposure to the chemotherapeutic 5-fluorouracil (5-FU).

Under the terms of the agreement, BTG will have exclusive rights to market, sell and distribute uridine triacetate for this indication in the US for up to 10 years from marketing approval. Wellstat will be responsible for completing development and regulatory filings and for product manufacture. BTG will pay Wellstat an upfront fee of $7.5 million as well as milestone payments upon NDA acceptance and approval and transfer pricing payments based on manufacturing costs and a significant percentage of net sales.

5-FU is a commonly used first-line or adjunctive treatment for colorectal, breast, head and neck tumours. According to the National Institutes of Health Federal Register, some 275,000 US patients receive 5-FU therapy annually of whom around 8,000 will experience a dangerous toxic reaction, which causes the death of around 1300 patients each year. Systemic overexposure of 5-FU can result from impaired clearance, usually caused by a genetic deficiency of an enzyme called DPD, or from medication errors. Uridine triacetate reduces the incorporation of toxic 5-FU metabolites into non-cancerous cells.

While uridine triacetate has not yet received marketing approval, it will continue to be available to patients in the US under emergency use INDs and an expanded access protocol. It is anticipated that the New Drug Application will be submitted during the first half of 2013. The compound has been granted orphan drug designation both in the United States and outside the US. Until approval, any enquiries or requests for uridine triacetate should be directed to Wellstat.

Louise Makin, BTG’s Chief Executive Officer, commented: “There is currently no available antidote for accidental 5-FU overexposure, so uridine triacetate will meet a real need if approved. As an oncology antidote, it is an excellent fit with our existing US acute care business and will enable us to leverage the sales team and back office support infrastructure which we have already put in place.”

David M. Wohlstadter, Vice President of Licensing and Business Development for Wellstat, commented,“We are delighted to be working with BTG to address this important unmet medical need. BTG are dedicated to marketing and commercializing antidote therapies such as CroFab® and DigiFab® and they have shown impressive growth and focus in implementing their strategic goals. We believe our investigational antidote has potential to be a safe and highly effective therapy in overexposure to 5-FU, and that our agreement with BTG further validates the strength and depth of Wellstat’s drug discovery, research and development capabilities.”

For further information contact:

BTG
Andy Burrows, Director of Investor Relations
T: +44 (0)20 7575 1741; Mobile: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer / T: +44 (0)20 7575 0000

Financial Dynamics
Ben Atwell / T: +44 (0)20 7831 3113

About BTG
BTG (btgplc.com) is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products.

About Wellstat
Wellstat Therapeutics Corporation (wellstat.com) is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Wellstat Therapeutics is committed to discovering, developing and commercializing products that will provide new and improved treatments for patients in the fields of oncology and metabolic, neurometabolic and neurodegenerative diseases. Wellstat Therapeutics is part of the Wellstat group of companies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Profile / Press Room |
Publisher Contact: BioCompatibles.com 
+44(0)12 5273 2710
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)